LABT — Lakewood-Amedex Biotherapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079272 ·
Last close
$0.79
Market Cap
$1.88M
52W High
$98.20
52W Low
$0.76
ADV30
2,412,236
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,789,660 | -3,772,008 | 4,960,009 | 2,584,774 | 628,926 |
| Mar 2026 | 0 | — | -886,750 | -923,291 | 196,343 | 11,709 | 3,037,991 |
| Dec 2025 | 0 | — | -712,060 | -744,918 | 481,598 | 236,400 | 2,446,135 |
| Sep 2025 | 0 | — | -1,880,317 | -1,907,159 | 985,118 | 658,410 | 2,251,434 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,914,001
Investing CF
$841,000
Financing CF
$325,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.87
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-54,274,421
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-3,999,835
Pretax Income TTM
$-4,114,985
Interest Exp TTM
$115,150
Analysts
1
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,772,370 | -3,847,637 | 481,598 | 2,446,135 | -1,964,537 | -1,944,698 |
| Dec 2024 | 0 | -4,026,820 | -4,855,405 | 1,070,581 | 660,970 | 409,611 | -5,723,322 |
| Dec 2023 | 0 | -8,636,719 | -8,281,960 | 6,893,904 | 2,335,577 | 4,558,327 | -6,816,114 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$196,343
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARTL | ARTELO BIOSCIENCES, INC. | $1.85M | $3.37 | — |
| RNAZ | Transcode Therapeutics, Inc. | $1.81M | $1.71 | — |
| VBIO | Valion Bio, Inc. | $1.96M | $2.21 | — |
| TCRT | Alaunos Therapeutics, Inc. | $1.98M | $0.78 | — |
| AGNPF | Grey Matters Health Inc. | $1.70M | $0.31 | — |
News headlines (Yahoo Finance, 1h cache)
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
2026-10-07 12:02 · Yahoo
Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections
2026-09-28 16:26 · Yahoo
Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates
2026-09-28 14:57 · Yahoo
LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-28 12:16 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
2026-09-28 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-24 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
2026-09-21 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
2026-09-18 12:13 · Yahoo
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:02 · Yahoo
LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers
2026-08-26 13:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.